Understanding how DMP1 affects phosphate levels and bone health
The role of DMP1 in FGF23-induced hypophosphatemia
This study is looking at how a protein called Dentin Matrix Protein 1 (DMP1) helps control phosphate levels in the body, especially for people with conditions like X-linked hypophosphatemia (XLH) and autosomal recessive hypophosphatemic rickets (ARHR), to find new ways to help improve bone health and reduce pain.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11014999 on NIH RePORTER |
What this research studies
This research investigates the role of Dentin Matrix Protein 1 (DMP1) in regulating phosphate levels in the body, particularly in conditions like X-linked hypophosphatemia (XLH) and autosomal recessive hypophosphatemic rickets (ARHR). The study aims to explore how excess levels of Fibroblast Growth Factor 23 (FGF23) lead to low phosphate levels, which can cause severe bone pain and fractures. By examining the mechanisms of DMP1 and its interaction with FGF23, the research seeks to identify potential long-term therapies that could improve bone growth and mineralization for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with X-linked hypophosphatemia or autosomal recessive hypophosphatemic rickets.
Not a fit: Patients with normal phosphate levels or those not affected by hypophosphatemic disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients suffering from bone disorders related to low phosphate levels.
How similar studies have performed: Previous research has shown promising results with therapies targeting FGF23, indicating potential for success in this area.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Martin, Aline C — Northwestern University at Chicago
- Study coordinator: Martin, Aline C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.